▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4228 by analyst upside · 2026-11-08
RNLXY
Renalytix Plc
Healthcare · Market Cap $50M · P/E 0x
ANALYST PRICE TARGET
-92.4%
implied upside to consensus target
Current Price $3.7
Consensus Target $0.28
Bull Target $0.28
Bear Target $0.28
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $1.0
52-Week High $138.75
YTD Return -7.3%
FUNDAMENTALS
Market Cap $50M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.0
52-Week High $138.75
Current Price $3.7
Bear Target $0.28
Bull Target $0.28
● Now $3.7 ● Target $0.28
TRADING DATA
Avg Volume 3K
YTD Return -7.3%
Analyst Count 1
Consensus Buy
Upside to Target -92.4%
Last Updated 2026-11-08

ANALYST SUMMARY

Renalytix Plc (RNLXY) is currently trading at $3.7 with a Wall Street consensus price target of $0.28, which is 92.4% below the current price over the next 12 months. 1 analysts currently cover RNLXY, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $0.28, while the most cautious has a target of $0.28.

RNLXY operates in the Healthcare sector with a market capitalisation of $50M. The stock is down 7.3% year-to-date and is currently trading near the lower end of its 52-week range of $1.0 – $138.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →